- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03711123
Group Metacognitive Therapy vs Clinical Management for Depression
A Randomized Controlled Trial of the Effectiveness of Group Metacognitive Therapy vs Clinical Management for Patients With Major Depressive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Major depressive disorder (MDD) is a disabling condition which adversely affects a person's family, work or school life, sleeping and eating habits, and general health.
Cognitive-behavioral therapy (CBT) is a well established effective recommended treatment for MDD. However, only 40-58 % of patients receiving CBT may be classified as recovered using clinical significant change assessed by the Beck Depression Inventory and only between one-third and one quarter of patients receiving CBT remain recovered 18 months after treatment.
A new treatment approach to MDD is Metacognitive Therapy (MCT). In this treatment approach, MDD is conceptualized as being maintained by rumination and meta-cognitions. Treatment seeks to challenge and change specific meta-cognitions and rumination, through behavioural experiments and verbal reattribution. There is accumulating evidence that MCT is effective in the treatment of depression, both individualized and in Groups. A recent pilot study indicated effectiveness above that of CBT. However, the results need to be tested in a randomized controlled trial with a larger sample of patients and a comparison group of active treatment.
The purpose of this trial is to evaluate the effectiveness of Group MCT treatment compared to clinical management included guided self-help and to explore which factors that are associated with depressive symptom outcome in terms of psychological factors, biomarker in terms of heart rate variabilities and polygenic risk score.
The study will be a randomized controlled, trial comprising 64 patients with a primary diagnosis of major depressive disorder (DSM-IV; American Psychiatric Association (APA), 1994). Experienced diagnosticians will assess all patients by using structural interviews such as Structured Clinical Interview for DSM-IV, axis I(SCID I), and axis II disorders (SCID II) and the Hamilton Rating Scale for Depression (HDRS).
All patients will be randomized in blocks to two groups in order to compare the following conditions: Group MCT of 10 weekly sessions lasting 90 minutes and a clinical management condition With 10 weekly individualized sessions up to 60 minutes duration.
Both between-subjects and within-subjects comparisons will be conducted. The research trial will be conducted at an outpatient specialist practice in Drammen, Norway.
The treatment will be administered according to the originators published treatment protocols for MCT for depression. Independent assessors will assess adherence and quality of treatment.
Independent experts will assess the quality of treatment by inspection of a sampling of video-recorded treatments. Using checklists session-by-session will ensure adherence of the therapy. Responsible investigator and supervisors will be using video of all treatment sessions to assess adherence to the treatment condition.
All patients referred for the study will be consecutively assessed at intake (SCID-I + II, HDRS-17). Based on diagnosis and criteria for inclusion and exclusion, the patients will be asked to volunteer to participate in the study and confirm by signing a form of consent.
Patients will be randomized to one of two conditions. Patients will be asked to self-rate symptoms on a battery of self-report questionnaires.
The patients will be assessed prior to treatment, by 10 weeks in treatment, and at six months and at one and two years of follow-up.
Reassessment of the diagnosis and symptom severity is made by post-treatment.
Criteria for recovery will be: Jacobsen criteria of a minimum change and patients crossing the cut-off point on two measures: The HDRS-17 and Beck Depression Inventory (BDI). Other outcome measures will include:
Reduction of depressive symptoms as measured by self-report questionnaires Number of patients with no MDD diagnosis based on SCID-I after treatment Relapse rate during six months and at one and two years follow-up The proportion of responders as measured by the HDRS-17 and BDI and those who no longer fulfil the conditions for a MDD diagnosis after 10 weeks (post-treatment) and by 6 months and one and two years follow-up.
The secondary efficacy variables will be the proportion of responders at 10 weeks (post-treatment) and six months and by one and two years follow-up as measured by the other symptom measures.
A comparison between the two groups of patients will be conducted at 10 weeks (post-treatment) and there will be 6 month and at one- and two years.
A within group analyses will be conducted in order to estimate effect sizes and significant clinical change estimates.
A computer provided by University of Oslo (UiO) will generate the randomization list.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Toril Dammen, PhD
- Phone Number: 4790163433
- Email: toril.dammen@medisin.uio.no
Study Locations
-
-
Buskerud
-
Drammen, Buskerud, Norway, 3014
- Recruiting
- Specialist practice Dr Toril Dammen
-
Contact:
- Toril Dammen, PhD
- Phone Number: 4790163433
- Email: toril.dammen@medisin.uio.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- MDD is primary problem
- 18-65 years
- stable on medication for at least 8 weeks or medication free
- able to understand and write the Norwegian Language
- signed written informed consent prior to participation
Exclusion Criteria:
- Medical or physical condition underlying depression
- psychosis or organic mental illness
- current suicide intent
- not willing to Accept no changes in medication during treatment
- not willing to Accept random allocation
- cluster A or cluster B personality disorder
- alcohol/substance dependence/abuse
- concurrent psychological treatment or evidence based psychotherapy for depression past year
- bipolar disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group metacognitive therapy (GMCT)
10 weekly sessions of GMCT With 90 minutes duration
|
10 weekly Group session of 90 minutes duration
|
ACTIVE_COMPARATOR: Clinical Management
10 weekly individual sessions with up to 60 minutes duration
|
10 weekly individual sessions With clinical management including guided self-help
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depression
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Beck Depression Inventory
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in diagnosis
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
SCID-I
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in depression
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Hamilton Depression Rating Scale 17-item version (HDRS-17) yielding total scores from 0 (least severe) to 52 (most severe)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in rumination
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Ruminative Responses Scale (RRS)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in positive beliefs
Time Frame: baseline to 10 weeks, 6 months, 12 months and 24 months follow up
|
Positive Beliefs about rumination scale (PBRS)
|
baseline to 10 weeks, 6 months, 12 months and 24 months follow up
|
Change in Negative beliefs
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Negative beliefs about rumination scale (NBRS)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in metacognitions
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Metacognitions questionnaire-30 (MCQ-30)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in personality
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Distressed type personality (DS-14)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in dysfunctional attitudes and beliefs
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Dysfunctional attitude scales (DAS)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in resilience
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Resilience Scale for adults (RSA)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in anxiety
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Beck Anxiety Inventory (BAI)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Change in sleep
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Pittsburgh sleep quality inventory (PSQI)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
change in report of executive function
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Behaviour Rating of Executive Function (BRIEF-A)
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
change in personality diagnoses
Time Frame: baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
SCID-II
|
baseline to 10 weeks (post treatment), 6 months, 12 months and 24 months follow up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/673-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Group metacognitive therapy
-
University of LiverpoolLiverpool University Hospitals NHS Foundation Trust; University of ManchesterTerminatedDepression | Quality of Life | Cancer | AnxietyUnited Kingdom
-
University of Southern DenmarkCenter for Kognitive Terapier og SupervisionUnknown
-
University of ManchesterCompletedGeneralized Anxiety DisorderUnited Kingdom
-
University of HaifaCompleted
-
University of WarsawMedical University of Warsaw; Institute of Psychiatry and Neurology, WarsawCompletedPsychotic Disorders | Schizophrenia
-
University of LiverpoolMedical Research CouncilCompletedDepression | Cancer | AnxietyUnited Kingdom
-
University of ManchesterManchester University NHS Foundation Trust; Pennine Care NHS Foundation TrustRecruitingDepression | AnxietyUnited Kingdom
-
University Hospital TuebingenGerman Research FoundationCompletedAttention Deficit Hyperactivity DisorderGermany
-
University of ManchesterGreater Manchester Mental Health NHS Foundation TrustActive, not recruiting
-
University Hospital, Strasbourg, FranceTerminated